Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).
暂无分享,去创建一个
G. Sonpavde | J. Bull | J. Levitt | K. Slawin | D. Spencer | J. Mcmannis | Y. Bai | N. Lapteva | T. Dancsak | V. Hawkins | M. Seethammagari